|Systematic (IUPAC) name|
|Mol. mass||355.428 g/mol|
Nalmexone (INN; EN-1620A, UM-592), or nalmexone hydrochloride (USAN), is a semisynthetic, mixed opioid agonist-antagonist with analgesic and narcotic antagonist properties that was never marketed. In clinical studies it was found to have comparable analgesic efficacy to morphine, though with several-fold reduced potency. In addition, nalmexone's side effects, the most common of which were sleepiness and sweating, were reported to be similar to those of morphine, albeit with a noticeably higher degree of incidence.
- Macdonald F (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1395. ISBN 978-0-412-46630-4. Retrieved 11 May 2012.
- Casy AF, Parfitt RT (1986). Opioid Analgesics: Chemistry and Receptors. Springer. p. 55. ISBN 978-0-306-42130-3. Retrieved 11 May 2012.
- Loew GH, Berkowitz DS (1978). "Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics". Journal of Medicinal Chemistry 21 (1): 101–106. doi:10.1021/jm00199a018. PMID 73588.
- Forrest WH, Shroff PF, Mahler DL (1972). "Analgesic and other effects of nalmexone in man". Clinical Pharmacology and Therapeutics 13 (4): 520–525. PMID 4557582.
- National Research Council (U.S.). Committee on Problems of Drug Dependence; American Medical Association. Committee on Alcoholism and Drug Dependence; American Medical Association. Council on Mental Health; National Academy of Sciences (U.S.) (1969). Bulletin, problems of drug dependence. National Academies. p. 5873. NAP:10503. Retrieved 11 May 2012.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|